Physician profile
Todd A Rave
NPI 1407982978
$7,828.32
in general payments reported to CMS, 2019-2025
26 companies · $234 in 2025
The $234 reported for 2025 was less than what a typical Neurology (Psychiatry & Neurology) provider received nationally (typical 2025 total: $454).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,188 · 2020: $360 · 2021: $1,312 · 2022: $1,499 · 2023: $1,454 · 2024: $781 · 2025: $234.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,469.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,469.39 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $1,298.49 | 2019-2025 | |
| Biogen, INC. | $1,106.78 | 2019-2024 | Tysabri |
| Emd Serono, INC. | $869.34 | 2019-2024 | Mavenclad, Mavenclad |
| Celgene Corporation | $577.02 | 2019-2024 | Zeposia |
| Teva Pharmaceuticals USA, INC. | $448.10 | 2019-2023 | Austedo Xr |
| Tg Therapeutics, INC. | $346.53 | 2022-2023 | |
| Janssen Pharmaceuticals, INC | $303.20 | 2021-2022 | |
| Alexion Pharmaceuticals, INC. | $256.61 | 2019-2024 | Ultomiris |
| E.R. Squibb & Sons, L.L.C. | $249.99 | 2021-2024 | Zeposia |
| Abbvie INC. | $242.33 | 2022-2025 | |
| Neurelis, INC. | $235.86 | 2021-2023 | Valtoco |
| Mdd US Operations, LLC | $200.38 | 2019-2020 | |
| Genzyme Corporation | $193.14 | 2022-2023 | |
| Inspire Medical Systems, INC. | $188.82 | 2023-2024 | Inspire |
| Acadia Pharmaceuticals INC | $173.18 | 2020-2022 |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $156.23 | 2023 | |
| Jazz Pharmaceuticals INC. | $125.00 | 2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $125.00 | 2023 | Hyqvia |
| Lilly USA, LLC | $118.09 | 2019-2024 | Reyvow, Emgality |
| Allergan, INC. | $117.66 | 2019-2022 | |
| Eisai INC. | $108.42 | 2023-2024 | |
| Corium, LLC | $105.87 | 2023 | Adlarity |
| Biohaven Pharmaceutical Holding Company LTD. | $105.75 | 2022 | |
| Acorda Therapeutics, INC | $104.04 | 2019 | |
| Harmony Biosciences LLC | $54.48 | 2023-2025 | Wakix |
| Sandoz INC. | $18.01 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Todd Rave listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.